RADIANT Trial Shows Significant Glycemic Gains with Omnipod® 5 After MDI Transition Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology through its Omnipod® brand, has released new clinical data from its RADIANT study, demonstrating significant glycemic…
FDA Clears Quibim’s QP-Prostate® CAD for Lesion Detection and Diagnosis Quibim, a global leader in imaging biomarkers for precision medicine, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting 510(k) clearance for its QP-Prostate® CAD…
Nexus Pharmaceuticals Expands Portfolio with the Launch of Tranexamic Acid Nexus Pharmaceuticals, LLC has announced the official launch of Tranexamic Acid, marking a significant milestone in the company’s ongoing commitment to providing life-saving medications. This addition to Nexus’ growing pharmaceutical…
Adagio Medical Announces Key Clinical and Business Developments Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies, has provided an update on its strategic focus and progress in advancing ventricular tachycardia (VT) solutions. The company continues to…
CEL-SCI Prices $2.5M Offering to Advance Cancer Immunotherapy Development CEL-SCI Corporation (NYSE American: CVM), a biotechnology company focused on cancer immunotherapy, has announced the pricing of a best-efforts public offering to raise approximately $2.56 million. The offering comprises 16,000,000 shares…
Egle Therapeutics Secures €9.3 Million in State Funding to Advance Treg-Targeting Immunotherapies Egle Therapeutics, a clinical-stage biotechnology company specializing in the development of immunotherapies targeting regulatory T cells (Tregs), has secured €9.3 million in state funding under the “Innovations in…
Forth Tx Debuts with Sofinnova’s Support to Transform Fibrosis Treatment Forth Therapeutics (Forth Tx), a biotechnology company pioneering next-generation precision therapeutics for fibrosis, officially launches today with significant backing from Sofinnova Partners, a leading European life sciences venture capital firm,…
BioClec Launches to Transform Alzheimer’s Treatment with Sofinnova’s Backing BioClec, a pioneering biotechnology company dedicated to revolutionizing treatments for Alzheimer’s disease, has officially launched. The company emerges from Biovelocita II, Sofinnova Partners’ €165 million biotech acceleration program, and is focused…
Sofinnova Partners’ Biotech Fund Exceeds Target at €165M Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm with offices in Paris, London, and Milan, has announced the final close of Sofinnova Biovelocita II. The fund exceeded its target,…
Protembis Forms Scientific Advisory Board of Leading Heart Experts Protembis, a privately-held cardiovascular medical device company, has announced the establishment of a Scientific Advisory Board (SAB) to provide strategic guidance and expert counsel on scientific and clinical matters. The SAB…